A phase II clinical trial of Dazodalibep in Focal segmental glomerulosclerosis
Latest Information Update: 05 Mar 2022
At a glance
- Drugs Dazodalibep (Primary)
- Indications Focal segmental glomerulosclerosis
- Focus Therapeutic Use
- 01 Mar 2022 According to a Horizon Therapeutics plc media release, this trial is expected to begin in the fourth quarter of 2022.
- 03 Nov 2021 According to a Horizon Therapeutics plc media release, this trial is expected to begin in the second half of 2022.
- 01 Oct 2021 New trial record